Igor Mett
- Immunology top 2%
- interferon and immune responses 2
- Cancer Research top 2%
- NF-κB Signaling Pathways 3
- Molecular Biology top 5%
- Cell death mechanisms and regulation 4
- RNA Interference and Gene Delivery 3
- RNA and protein synthesis mechanisms 3
- Mitochondrial Function and Pathology 2
- Oncology top 5%
- Cell Biology top 5%
-
- Enzyme Structure and Function 4
-
- Amino Acid Enzymes and Metabolism 2
Igor Mett
17 papers receiving 3.1k citations
Hit Papers
Peers
Comparison fields: 5 of 96
- Immunology 1.1k
- Cancer Research 704
- Molecular Biology 2.5k
- Oncology 475
- Cell Biology 275
Countries citing papers authored by Igor Mett
This map shows the geographic impact of Igor Mett's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Igor Mett with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Igor Mett more than expected).
Fields of papers citing papers by Igor Mett
This network shows the impact of papers produced by Igor Mett. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Igor Mett. The network helps show where Igor Mett may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Igor Mett, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2011 | 119 | |
| 2 | PF-04523655 (REDD14), an siRNA Compound Targeting RTP801, Penetrates Retinal Cells Producing Target Gene Knockdown and Avoiding TLR3 Activation | 2009 | 4 |
| 3 | RTP801i: A Novel Anti–Angiogenic Strategy Superior to and Cooperative With VEGF–A Blockade in Suppressing CNV | 2006 | 3 |
| 4 | Diabetes–Induced Abnormalities in Retinal Vascular Permeability (RVP) & Electroretinogram (ERG) Are Normalized in RTP801/REDD1 Knockout (KO) Mice | 2005 | 1 |
| 5 | 2004 | 105 | |
| 6 | 2002 | 479 | |
| 7 | Targeted Disruption of the Mouse Caspase 8 Gene Ablates Cell Death Induction by the TNF Receptors, Fas/Apo1, and DR3 and Is Lethal Prenatallybreakdown → | 1998 | 999 |
| 8 | 1998 | 25 | |
| 9 | Exploring cell death mechanisms by analyzing signaling cascades of the TNF/NGF receptor family. | 1996 | 27 |
| 10 | A Novel Protein That Interacts with the Death Domain of Fas/APO1 Contains a Sequence Motif Related to the Death Domainbreakdown → | 1995 | 850 |
| 11 | 1995 | 321 | |
| 12 | 1995 | 56 | |
| 13 | 1994 | 2 | |
| 14 | 1993 | 41 | |
| 15 | 1993 | 52 | |
| 16 | 1992 | 35 | |
| 17 | 1992 | 32 | |
| 18 | [Molecular cloning and structural-functional analysis of the arginine biosynthesis genes of the thermophilic bacterium Bacillus stearothermophilus]. | 1990 | 13 |
About Igor Mett
Igor Mett is a scholar working on Ophthalmology, Biochemistry and Cancer Research, having authored 18 papers that have together received 3.2k indexed citations. Recurring topics across this work include Cell death mechanisms and regulation (4 papers), Enzyme Structure and Function (4 papers), RNA Interference and Gene Delivery (3 papers), NF-κB Signaling Pathways (3 papers), RNA and protein synthesis mechanisms (3 papers), Amino Acid Enzymes and Metabolism (2 papers), interferon and immune responses (2 papers) and Mitochondrial Function and Pathology (2 papers). The work is most often cited by research in Immunology (1.1k citations), Cancer Research (704 citations) and Molecular Biology (2.5k citations). Igor Mett has collaborated with scholars based in Israel, France and United States. Frequent co-authors include David Wallach, Eugene Varfolomeev, Mark Boldin, Jacques Camonis, Zeev Pancer, Tama Sobe, Tsvee Lapidot, Marcus Schuchmann, Órit Kollet and Helmut Holtmann. Their work appears in journals such as Journal of Biological Chemistry, Investigative Ophthalmology & Visual Science, Gene, Current Opinion in Immunology and Cell Death and Disease.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.